Interim 18F-FDG PET/CT During Chemoradiation Therapy in the Management of Head and Neck Cancer Patients: A Systematic Review.

[1]  V. Bray,et al.  Prognostic Value of 2-[(18)F] Fluoro-2-deoxy-D-glucose Positron Emission Tomography-Computed Tomography Scan Carried out During and After Radiation Therapy for Head and Neck Cancer Using Visual Therapy Response Interpretation Criteria. , 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

[2]  Mark T Lee,et al.  18F‐FDG PET–CT performed before and during radiation therapy of head and neck squamous cell carcinoma: Are they independent or complementary to each other? , 2016, Journal of medical imaging and radiation oncology.

[3]  B. Loo,et al.  Prognostic value of midtreatment FDG‐PET in oropharyngeal cancer , 2016, Head & neck.

[4]  T. Vercauteren,et al.  Intensity modulated arc therapy implementation in a three phase adaptive 18F-FDG-PET voxel intensity-based planning strategy for head-and-neck cancer , 2016, Radiation Oncology.

[5]  E. Ioachim,et al.  Biomarkers of head and neck cancer, tools or a gordian knot? , 2015, International journal of clinical and experimental medicine.

[6]  Mark T Lee,et al.  Prognostic role of metabolic parameters of 18F-FDG PET-CT scan performed during radiation therapy in locally advanced head and neck squamous cell carcinoma , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  M. Uder,et al.  Single‐cycle induction chemotherapy followed by chemoradiotherapy or surgery in patients with head and neck cancer: What are the best predictors of remission and prognosis? , 2015, Cancer.

[8]  M. Nicolau,et al.  Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data , 2015, Oncotarget.

[9]  Steven Sourbron,et al.  Alterations in anatomic and functional imaging parameters with repeated FDG PET-CT and MRI during radiotherapy for head and neck cancer: a pilot study , 2015, BMC Cancer.

[10]  V. Grégoire,et al.  PET imaging biomarkers in head and neck cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  Eric J. W. Visser,et al.  FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  S. Yang,et al.  Interim FDG PET/CT for predicting the outcome in patients with head and neck cancer , 2014, The Laryngoscope.

[13]  O. Hoekstra,et al.  Diffusion-weighted EPI- and HASTE-MRI and 18F-FDG-PET-CT early during chemoradiotherapy in advanced head and neck cancer. , 2014, Quantitative imaging in medicine and surgery.

[14]  S. Korreman,et al.  Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  Dong Soo Lee,et al.  Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis in Head and Neck Cancer: A Systematic Review and Meta-Analysis , 2014, The Journal of Nuclear Medicine.

[16]  D. Yan,et al.  Early Treatment Response Monitoring Using 2-Deoxy-2-[18F]fluoro-D-glucose Positron Emission Tomography Imaging during Fractionated Radiotherapy of Head Neck Cancer Xenografts , 2014, BioMed research international.

[17]  R. Marianowski,et al.  Prognostic value of volumetric parameters measured by 18F-FDG PET/CT in patients with head and neck squamous cell carcinoma , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  Wim J. G. Oyen,et al.  Pathology-based validation of FDG PET segmentation tools for volume assessment of lymph node metastases from head and neck cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  D. Brizel,et al.  Using FDG-PET to Measure Early Treatment Response in Head and Neck Squamous Cell Carcinoma: Quantifying Intrinsic Variability in Order to Understand Treatment-Induced Change , 2013, American Journal of Neuroradiology.

[20]  T. Vercauteren,et al.  Three-phase adaptive dose-painting-by-numbers for head-and-neck cancer: initial results of the phase I clinical trial. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  B. Hoeben,et al.  18F-FLT PET During Radiotherapy or Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma Is an Early Predictor of Outcome , 2013, The Journal of Nuclear Medicine.

[22]  Y. Nishiyama,et al.  Changes in 18F-fluorothymidine and 18F-fluorodeoxyglucose positron emission tomography imaging in patients with head and neck cancer treated with chemoradiotherapy , 2013, Annals of Nuclear Medicine.

[23]  L. Pérez-Romasanta,et al.  Tumor volume delineation in head and neck cancer with 18-fluor-fluorodeoxiglucose positron emission tomography: adaptive thresholding method applied to primary tumors and metastatic lymph nodes , 2012, Clinical and Translational Oncology.

[24]  Steen Jakobsen,et al.  FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  Yuka Yamamoto,et al.  Usefulness of 3′-Deoxy-3′-18F-Fluorothymidine PET for Predicting Early Response to Chemoradiotherapy in Head and Neck Cancer , 2012, The Journal of Nuclear Medicine.

[26]  Michael Baumann,et al.  Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[27]  R. Abgral,et al.  Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  Hua Wu,et al.  Biological Response of Nasopharyngeal Carcinoma to Radiation Therapy: A Pilot Study Using Serial 18F-FDG PET/CT Scans , 2012, Cancer investigation.

[29]  E. Monteiro,et al.  Positron emission tomography in the detection of occult primary head and neck carcinoma: a retrospective study , 2012, Head & neck oncology.

[30]  P. Castaldi,et al.  Can "early" and "late"18F-FDG PET-CT be used as prognostic factors for the clinical outcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy? , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[31]  Peter Smeets,et al.  Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[32]  Xavier Geets,et al.  Adaptive functional image-guided IMRT in pharyngo-laryngeal squamous cell carcinoma: is the gain in dose distribution worth the effort? , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[33]  Fréderic Duprez,et al.  Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[34]  G. Storme,et al.  Can 18-FDG-PET during radiotherapy replace post-therapy scanning for detection/demonstration of tumor response in head-and-neck cancer? , 2011, International journal of radiation oncology, biology, physics.

[35]  Fréderic Duprez,et al.  Adaptive dose painting by numbers for head-and-neck cancer. , 2011, International journal of radiation oncology, biology, physics.

[36]  R. Kloiber,et al.  Clinical utility of PET/CT in the evaluation of head and neck squamous cell carcinoma with an unknown primary: A prospective clinical trial , 2011, Head & neck.

[37]  B. Sanghera,et al.  Adaptive 18fluoro-2-deoxyglucose positron emission tomography/computed tomography-based target volume delineation in radiotherapy planning of head and neck cancer. , 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).

[38]  Paul N. Span,et al.  Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[39]  M. Baumann,et al.  Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[40]  I. Kayani,et al.  The potential advantages of (18)FDG PET/CT-based target volume delineation in radiotherapy planning of head and neck cancer. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[41]  Johan Bussink,et al.  PET-CT for response assessment and treatment adaptation in head and neck cancer. , 2010, The Lancet. Oncology.

[42]  Xavier Geets,et al.  Assessment by a deformable registration method of the volumetric and positional changes of target volumes and organs at risk in pharyngo-laryngeal tumors treated with concomitant chemo-radiation. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[43]  Xavier Geets,et al.  Adaptive radiotherapy of head and neck cancer. , 2010, Seminars in radiation oncology.

[44]  G. Storme,et al.  Can 18F-FDG-PET response during radiotherapy be used as a predictive factor for the outcome of head and neck cancer patients? , 2010, Nuclear medicine communications.

[45]  W. Mendenhall,et al.  Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site , 2009, The Laryngoscope.

[46]  Nancy Lee,et al.  PET Monitoring of Therapy Response in Head and Neck Squamous Cell Carcinoma , 2009, Journal of Nuclear Medicine.

[47]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[48]  M. Baumann,et al.  Serial FDG-PET on patients with head and neck cancer: Implications for radiation therapy , 2009, International journal of radiation biology.

[49]  M. Kessler,et al.  Correlation between pretreatment FDG-PET biological target volume and anatomical location of failure after radiation therapy for head and neck cancers. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[50]  Aswin L Hoffmann,et al.  Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer. , 2007, International journal of radiation oncology, biology, physics.

[51]  Xavier Geets,et al.  Adaptive biological image-guided IMRT with anatomic and functional imaging in pharyngo-laryngeal tumors: impact on target volume delineation and dose distribution using helical tomotherapy. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[52]  Barbara Vanderstraeten,et al.  Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer. , 2007, International journal of radiation oncology, biology, physics.

[53]  James M Galvin,et al.  Intensity modulating and other radiation therapy devices for dose painting. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  Anne Bol,et al.  A gradient-based method for segmenting FDG-PET images: methodology and validation , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[55]  Daniela Thorwarth,et al.  Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[56]  J. Buatti,et al.  The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. , 2005, International journal of radiation oncology, biology, physics.

[57]  L. Weih,et al.  Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer , 2005, Head & neck.

[58]  Søren M Bentzen,et al.  Theragnostic imaging for radiation oncology: dose-painting by numbers. , 2005, The Lancet. Oncology.

[59]  Matthias Reimold,et al.  Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[60]  C C Ling,et al.  Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. , 2000, International journal of radiation oncology, biology, physics.

[61]  K. Herholz,et al.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.